Clinical trial · Observational
Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device
NCT04778878CI-TRIAL-00094097APPScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mediracer® NCS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (16)
- measure
- Nerve conductivity
- timeFrame
- 6 weeks
- description
- Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS
- measure
- Nerve conductivity
- timeFrame
- 12 weeks
- description
- Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS
- measure
- Nerve conductivity
- timeFrame
- 18 weeks
- description
- Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS
- measure
- Nerve conductivity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent 2. Planned initiation of oxaliplatin-, vincristine- or docetaxel-containing chemotherapy regimen \[FOLFOX, XELOX, (R)-CHOP/CHOEP/CVOP, docetaxel, docetaxel-doxorubicin\] 3. Age \>18y 4. ECOG 0-2 5. Patient compliant with the study procedures Exclusion Criteria: 1. Patient not fit/suitable for aforementioned chemotherapy regimen at baseline 2. Any prior postoperative or post-traumatic conditions affecting the sensory and/or motoric peripheral nerves 3. General vulnerability affecting the participation in the trial
References
Publications (0)
Data not yet available
No reference posted for this study.